141 related articles for article (PubMed ID: 37972138)
1. Improved sleep in adults with atopic dermatitis using the treatment dupilumab.
Br J Dermatol; 2023 Nov; 189(6):e106. PubMed ID: 37972138
[No Abstract] [Full Text] [Related]
2. A detailed evaluation of the effect of dupilumab on sleep in adults with atopic dermatitis.
Lee EY; Drucker AM
Br J Dermatol; 2023 Nov; 189(6):649-655. PubMed ID: 37658831
[No Abstract] [Full Text] [Related]
3. Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature.
Magdaleno-Tapial J; Valenzuela-Oñate C; García-Legaz-Martínez M; Martínez-Domenech Á; Pérez-Ferriols A
Australas J Dermatol; 2020 May; 61(2):e223-e225. PubMed ID: 31766073
[TBL] [Abstract][Full Text] [Related]
4. Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study.
Guédon C; Tauber M; Linder C; Paul C; Shourick J
Ann Dermatol Venereol; 2023 Sep; 150(3):215-216. PubMed ID: 37598014
[No Abstract] [Full Text] [Related]
5. Use of dupilumab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis.
Siegfried EC; Igelman S; Jaworski JC; Antaya RJ; Cordoro KM; Eichenfield LF; Levy ML; Paller AS
Pediatr Dermatol; 2019 Jan; 36(1):172-176. PubMed ID: 30675938
[No Abstract] [Full Text] [Related]
6. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J
Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials.
Tofte SJ; Papp K; Sadick N; Bohnert K; Simpson E; Thaçi D; Bieber T; Blauvelt A; Sofen H; Gooderham M; Chen Z; Gadkari A; Eckert L; Graham NMH; Pirozzi G; Ardeleanu M
J Am Assoc Nurse Pract; 2018 Sep; 30(9):529-541. PubMed ID: 30211823
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of recurrent exit site and tunnel infections caused by atopic dermatitis with dupilumab: A case report.
Noda R; Ishibashi Y
Ther Apher Dial; 2022 Feb; 26(1):255-256. PubMed ID: 34018694
[No Abstract] [Full Text] [Related]
9. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
[No Abstract] [Full Text] [Related]
10. Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients.
Ludriksone L; Elsner P; Schliemann S
J Dtsch Dermatol Ges; 2019 Dec; 17(12):1278-1280. PubMed ID: 31829527
[No Abstract] [Full Text] [Related]
11. Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review.
Akuffo-Addo E; Nicholas MN; Lansang P
J Cutan Med Surg; 2023; 27(2):177-178. PubMed ID: 36721993
[No Abstract] [Full Text] [Related]
12. [Psoriasis in dupilumab-treated atopic dermatitis].
Senner S; Eicher L; Aszodi N; Prinz JC; French LE; Wollenberg A
Hautarzt; 2020 May; 71(5):383-386. PubMed ID: 32179945
[TBL] [Abstract][Full Text] [Related]
13.
Doolan BJ; Yeon J; Baker DA; Whitfeld MJ
AIDS Res Hum Retroviruses; 2022 Feb; 38(2):76-79. PubMed ID: 34384267
[No Abstract] [Full Text] [Related]
14. Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic.
Hansel K; Patruno C; Antonelli E; Dal Bello G; Napolitano M; Fabbrocini G; Grieco T; Pellacani G; Fargnoli MC; Esposito M; Piras V; Zucca M; Girolomoni G; Stingeni L
Clin Exp Dermatol; 2022 Jan; 47(1):165-167. PubMed ID: 34309892
[No Abstract] [Full Text] [Related]
15. Successful dose reduction of dupilumab in atopic dermatitis.
Ardern-Jones MR; Buchanan EE; Njungu S; O'Driscoll D
Br J Dermatol; 2023 Apr; 188(5):678-679. PubMed ID: 36662536
[No Abstract] [Full Text] [Related]
16. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?
Mastorino L; Gelato F; Richiardi I; Cavaliere G; Quaglino P; Ortoncelli M; Ribero S
J Eur Acad Dermatol Venereol; 2023 May; 37(5):e691-e692. PubMed ID: 36688263
[No Abstract] [Full Text] [Related]
17. Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab.
Ferrucci S; Tavecchio S; Berti E; Angileri L
Clin Exp Dermatol; 2020 Jul; 45(5):625-626. PubMed ID: 32112580
[No Abstract] [Full Text] [Related]
18. Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-centre experience.
Simonetti O; Radi G; Diotallevi F; Molinelli E; Rizzetto G; Offidani A
Clin Exp Dermatol; 2021 Jul; 46(5):939-940. PubMed ID: 33576497
[No Abstract] [Full Text] [Related]
19. Serum IL-22 binding protein as a marker for atopic dermatitis activity and response to dupilumab treatment.
Varandas C; Pereira-Santos MC; Neto M; Sousa AE; Lopes A; Silva SL
Clin Exp Allergy; 2022 Jun; 52(6):820-823. PubMed ID: 35416344
[No Abstract] [Full Text] [Related]
20. Dupilumab for the Treatment of Atopic Dermatitis.
Ferreira S; Torres T
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):230-240. PubMed ID: 29422431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
